Cite
Mahdavi KD, Jordan SE, Barrows HR, et al. Treatment of Dementia With Bosutinib: An Open-Label Study of a Tyrosine Kinase Inhibitor. Neurol Clin Pract. 2021;11(3):e294-e302doi: 10.1212/CPJ.0000000000000918.
Mahdavi, K. D., Jordan, S. E., Barrows, H. R., Pravdic, M., Habelhah, B., Evans, N. E., Blades, R. B., Iovine, J. J., Becerra, S. A., Steiner, R. A., Chang, M., Kesari, S., Bystritsky, A., O'Connor, E., Gross, H., Pereles, F. S., Whitney, M., & Kuhn, T. (2021). Treatment of Dementia With Bosutinib: An Open-Label Study of a Tyrosine Kinase Inhibitor. Neurology. Clinical practice, 11(3), e294-e302. https://doi.org/10.1212/CPJ.0000000000000918
Mahdavi, Kennedy D, et al. "Treatment of Dementia With Bosutinib: An Open-Label Study of a Tyrosine Kinase Inhibitor." Neurology. Clinical practice vol. 11,3 (2021): e294-e302. doi: https://doi.org/10.1212/CPJ.0000000000000918
Mahdavi KD, Jordan SE, Barrows HR, Pravdic M, Habelhah B, Evans NE, Blades RB, Iovine JJ, Becerra SA, Steiner RA, Chang M, Kesari S, Bystritsky A, O'Connor E, Gross H, Pereles FS, Whitney M, Kuhn T. Treatment of Dementia With Bosutinib: An Open-Label Study of a Tyrosine Kinase Inhibitor. Neurol Clin Pract. 2021 Jun;11(3):e294-e302. doi: 10.1212/CPJ.0000000000000918. PMID: 34484904; PMCID: PMC8382351.
Copy
Download .nbib